The Journal of Allergy and Clinical Immunology: In Practice
Original ArticleIdentifying Patient Attitudinal Clusters Associated with Asthma Control: The European REALISE Survey
Key words
Abbreviations used
Cited by (0)
Funding for the survey and medical writing support was provided by Mundipharma International Limited.
Conflicts of interest: T. van der Molen is on the Certe Laboratories board; and has received research support from AstraZeneca, Almirall, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, and Teva. M. Fletcher has received honoraria (paid to Education for Health) from Almirall, Chiesi, Teva, Abbott Laboratories, AstraZeneca, Novartis AG, Novartis UK, Boehringer Ingelheim, Pfizer, and UCB; and has received travel support from Almirall UK, Teva, and Novartis AG. D. Price is on the boards for Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; has received consultancy fees from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; has received research support from UK National Health Service, British Lung Foundation, Aerocrine, AKL Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, Mundipharma, Napp, Novartis, Orion, Pfizer, Skyepharma, Takeda, Teva Pharmaceuticals, and Respiratory Effectiveness Group; has received lecture fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals; has received payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; has a patent with AKL Ltd; has received payment for developing educational presentations from GlaxoSmithKline, Novartis, and Mundipharma; has stock/stock options in AKL Ltd; has received travel support from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; has received funding for patient enrolment or completion of research from Almirall, Chiesi, Teva Pharmaceuticals, Zentiva, and Novartis (fees paid to Observational and Pragmatic Research Institute); is peer reviewer for grant committees of Medical Research Council (2014), Efficacy and Mechanism Evaluation programme (2012), and Health Technology Assessment (HTA) (2014); and owns 80% of Research in Real Life Ltd, 74% of the social enterprise Optimum Patient Care Ltd, UK, and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore.